$181.96
2.91% yesterday
Nasdaq, Nov 25, 10:07 pm CET
ISIN
US09062X1037
Symbol
BIIB

Biogen Stock price

$181.96
+31.53 20.96% 1M
+56.15 44.63% 6M
+29.04 18.99% YTD
+23.25 14.65% 1Y
-123.19 40.37% 3Y
-59.79 24.73% 5Y
-87.28 32.42% 10Y
+140.98 344.02% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+5.14 2.91%
ISIN
US09062X1037
Symbol
BIIB
Industry

New AI Insights on Biogen Insights AI Insights on Biogen

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$25.9b
Enterprise Value
$28.3b
Net debt
$2.3b
Cash
$4.0b
Shares outstanding
146.7m
Valuation (TTM | estimate)
P/E
16.2 | 11.4
P/S
2.6 | 2.6
EV/Sales
2.8 | 2.8
EV/FCF
12.5
P/B
1.4
Financial Health
Equity Ratio
59.6%
Return on Equity
9.8%
ROCE
11.1%
ROIC
10.3%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$10.1b | $10.0b
EBITDA
$3.3b | $3.3b
EBIT
$2.9b | $3.0b
Net Income
$1.6b | $2.3b
Free Cash Flow
$2.3b
Growth (TTM | estimate)
Revenue
4.8% | 3.0%
EBITDA
16.5% | 9.1%
EBIT
15.2% | 13.4%
Net Income
-0.4% | 39.5%
Free Cash Flow
28.0%
Margin (TTM | estimate)
Gross
75.2%
EBITDA
33.1% | 33.3%
EBIT
28.5%
Net
16.0% | 22.9%
Free Cash Flow
22.5%
More
EPS
$10.9
FCF per Share
$15.4
Short interest
5.0%
Employees
8k
Rev per Employee
$1.3m
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

42 Analysts have issued a Biogen forecast:

21x Buy
50%
21x Hold
50%

Analyst Opinions

42 Analysts have issued a Biogen forecast:

Buy
50%
Hold
50%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
10,066 10,066
5% 5%
100%
- Direct Costs 2,493 2,493
6% 6%
25%
7,574 7,574
4% 4%
75%
- Selling and Administrative Expenses 2,426 2,426
5% 5%
24%
- Research and Development Expense 1,780 1,780
14% 14%
18%
3,334 3,334
16% 16%
33%
- Depreciation and Amortization 466 466
25% 25%
5%
EBIT (Operating Income) EBIT 2,868 2,868
15% 15%
28%
Net Profit 1,609 1,609
0% 0%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
about 13 hours ago
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help pat...
Neutral
Business Wire
one day ago
TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment f...
Neutral
GlobeNewsWire
one day ago
CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in immunological conditions. Macrocyclic peptides have a unique profile with the potential to offer biologic-like efficacy and safety in an oral format, potentially disrup...
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today